AI주식인사이트AI Stock Insight
C

엠에프씨

432980KOSDAQ기초 의약물질 제조업

50.0 / 100

Reference Date: 2026-04-13

Financial Score22.5 / 40
News Sentiment12.5 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Slightly down 3.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

MFC is a specialized company in the development and production of active pharmaceutical ingredients (APIs) and key materials (e.g., KSM, PI), expanding its business across generic drugs and improved new drug materials. Key products include APIs for treating hypertension and hyperlipidemia, as well as improved new drug materials (e.g., MFC-TM001, MFC-GM001), leveraging patented crystal form and salt development technologies to enhance market competitiveness.

Number of Employees

65people

Average Salary

64.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
33.83Industry Average 33.453.0Point

Higher than industry avg (caution)

PBR
1.00Industry Average 2.037.0Point

Half of industry avg (excellent)

ROE
2.82Industry Average -4.293.5Point

Well below industry avg

Debt Ratio
0.40Industry Average 6.618.0Point

Half of industry avg (excellent)

Trend 2024~20251.0 / 10 points
Revenue Growth Rate
1.0 / 3

Avg ▲0.9% (1-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼79.7% (1-year basis)

ROE Trend
0.0 / 4

Avg ROE -1.2% (improving, 2yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (16%, downtrend)

Current 3,485Won52-week high 4,45552-week low 3,300
1-month return2.0Point

1m -3.06% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

11 totalPositive 0Neutral 11Negative 0
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-07
  • Neutral정기주주총회결과2026-03-31
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
  • Neutral[기재정정]의결권대리행사권유참고서류2026-03-25
  • Neutral감사보고서제출2026-03-23